Merck MRK announced that it has initiated a phase III called Shorespan-007 study on its lysine-specific demethylase 1 (LSD1) inhibitor, bomedemstat, for the treatment of patients with essential ...

Merck (NYSE:MRK) said a pivotal Phase 3 study for its drug Winrevair in the treatment of pulmonary arterial hypertension, or PAH, has met its primary endpoint. Topline results from the study, called ...

Keytruda demonstrated statistically significant and clinically meaningful improvement in OS compared to pre-operative chemotherapy. KEYNOTE 522 is the fourth study of a Keytruda-based regimen in an ...

On Wednesday, Merck & Co Inc (NYSE:MRK) released topline data from the KEYFORM-007 Phase 3 study of the fixed-dose combination of favezelimab and pembrolizumab versus the standard of care for ...